GFM
GLUE icon

GF Fund Management’s Monte Rosa Therapeutics GLUE Stock Holding History

GF Fund Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.9K Buy
1,453
+174
+14% +$3.33K ﹤0.01% 482
2025
Q4 		$20.1K Sell
1,279
-38
-3% -$512 ﹤0.01% 510
2025
Q3 		$9.76K Sell
1,317
-255
-16% -$1.35K ﹤0.01% 558
2025
Q2 		$7.09K Hold
1,572
– – ﹤0.01% 601
2025
Q1 		$7.29K Buy
1,572
+282
+22% +$1.73K ﹤0.01% 599
2024
Q4 		$8.95K Buy
+1,290
New +$9.68K ﹤0.01% 563

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

GF Fund Management's GLUE Position: Q1 2026 in Review

GF Fund Management increased its Monte Rosa Therapeutics (GLUE) stake by 14% in Q1 2026, buying an estimated $3.33K and bringing the position to 1,453 shares worth $23.9K. The position accounts for ﹤0.01% of the portfolio, ranked #482.

GF Fund Management first reported a position in GLUE in Q4 2024 and has held it in 6 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • GF Fund Management held 1,453 shares of Monte Rosa Therapeutics worth $23.9K as of Q1 2026.
  • GF Fund Management bought 174 Monte Rosa Therapeutics shares in Q1 2026, an estimated $3.33K.
  • Monte Rosa Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #482 holding.
  • GF Fund Management first reported a position in Monte Rosa Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.